ReviewMinerva gastroenterology2025
Controversies in management of Helicobacter pylori infection from a U.S. perspective: population screening and treatment.
Review in Minerva gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Helicobacter pylori is responsible for several gastrointestinal disorders, of which gastric cancer is the most concerning. Given the racial and ethnic disparities seen with H. pylori infection and gastric cancer in the U.S., certain populations (immigrants, non-white racial groups) remain at high-risk. While several guidelines recommend screening for H. pylori in these high-risk groups, specific guidance on how to implement population screening and the cost-effectiveness of this approach is lacking. Here we discuss several controversies including the cost-effectiveness and implementation of a population-based H. pylori screening program, empiric vs. tailored therapy based on antibiotic susceptibility, and the role of potassium-competitive acid blockers (PCABs) in H. pylori treatment. With the rapidly changing landscape of H. pylori management, here we review the latest studies and guidelines for practical clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.